This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Labriola, L.
Right arrow Articles by Elizalde, P. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labriola, L.
Right arrow Articles by Elizalde, P. V.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, February 2003, p. 1095-1111, Vol. 23, No. 3
0270-7306/03/$08.00+0     DOI: 10.1128/MCB.23.3.1095-1111.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells

Leticia Labriola,1 Mariana Salatino,1 Cecilia J. Proietti,1 Adalí Pecci,2 Omar A. Coso,2 Alberto R. Kornblihtt,2 Eduardo H. Charreau,1,2 and Patricia V. Elizalde1*

Instituto de Biología y Medicina Experimental,1 Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires 1428, Argentina2

Received 25 March 2002/ Returned for modification 16 May 2002/ Accepted 14 October 2002

The present study addresses the capacity of heregulin (HRG), a ligand of type I receptor tyrosine kinases, to transactivate the progesterone receptor (PR). For this purpose, we studied, on the one hand, an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female BALB/c mice and, on the other hand, the human breast cancer cell line T47D. HRG was able to exquisitely regulate biochemical attributes of PR in a way that mimicked PR activation by progestins. Thus, HRG treatment of primary cultures of epithelial cells of the progestin-dependent C4HD murine mammary tumor line and of T47D cells induced a decrease of protein levels of PRA and -B isoforms and the downregulation of progesterone-binding sites. HRG also promoted a significant increase in the percentage of PR localized in the nucleus in both cell types. DNA mobility shift assay revealed that HRG was able to induce PR binding to a progesterone response element (PRE) in C4HD and T47D cells. Transient transfections of C4HD and T47D cells with a plasmid containing a PRE upstream of a chloramphenicol acetyltransferase (CAT) gene demonstrated that HRG promoted a significant increase in CAT activity. In order to assess the molecular mechanisms underlying PR transactivation by HRG, we blocked ErbB-2 expression in C4HD and T47D cells by using antisense oligodeoxynucleotides to ErbB-2 mRNA, which resulted in the abolishment of HRG's capacity to induce PR binding to a PRE, as well as CAT activity in the transient-transfection assays. Although the inhibition of HRG binding to ErbB-3 by an anti-ErbB-3 monoclonal antibody suppressed HRG-induced PR activation, the abolishment of HRG binding to ErbB-4 had no effect on HRG activation of PR. To investigate the role of mitogen-activated protein kinases (MAPKs), we used the selective MEK1/MAPK inhibitor PD98059. Blockage of MAPK activation resulted in complete abrogation of HRG's capacity to induce PR binding to a PRE, as well as CAT activity. Finally, we demonstrate here for the first time that HRG-activated MAPK can phosphorylate both human and mouse PR in vitro.

* Corresponding author. Mailing address: Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental, Obligado 2490, Buenos Aires 1428, Argentina. Phone: 5411-4783-2869. Fax: 5411-4786-2564. E-mail: Elizalde{at}dna.uba.ar.

Molecular and Cellular Biology, February 2003, p. 1095-1111, Vol. 23, No. 3
0022-538X/03/$08.00+0     DOI: 10.1128/MCB.23.3.1095-1111.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lanari, C., Lamb, C. A, Fabris, V. T, Helguero, L. A, Soldati, R., Bottino, M. C., Giulianelli, S., Cerliani, J. P., Wargon, V., Molinolo, A. (2009). The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16: 333-350 [Abstract] [Full Text]  
  • Dressing, G. E, Hagan, C. R, Knutson, T. P, Daniel, A. R, Lange, C. A (2009). Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 16: 351-361 [Abstract] [Full Text]  
  • Miller, T. W., Perez-Torres, M., Narasanna, A., Guix, M., Stal, O., Perez-Tenorio, G., Gonzalez-Angulo, A. M., Hennessy, B. T., Mills, G. B., Kennedy, J. P., Lindsley, C. W., Arteaga, C. L. (2009). Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. Cancer Res. 69: 4192-4201 [Abstract] [Full Text]  
  • Proietti, C. J., Rosemblit, C., Beguelin, W., Rivas, M. A., Diaz Flaque, M. C., Charreau, E. H., Schillaci, R., Elizalde, P. V. (2009). Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth. Mol. Cell. Biol. 29: 1249-1265 [Abstract] [Full Text]  
  • Daniel, A. R., Faivre, E. J., Lange, C. A. (2007). Phosphorylation-Dependent Antagonism of Sumoylation Derepresses Progesterone Receptor Action in Breast Cancer Cells. Mol. Endocrinol. 21: 2890-2906 [Abstract] [Full Text]  
  • Carnevale, R. P., Proietti, C. J., Salatino, M., Urtreger, A., Peluffo, G., Edwards, D. P., Boonyaratanakornkit, V., Charreau, E. H., de Kier Joffe, E. B., Schillaci, R., Elizalde, P. V. (2007). Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways. Mol. Endocrinol. 21: 1335-1358 [Abstract] [Full Text]  
  • An, B.-S., Selva, D. M., Hammond, G. L., Rivero-Muller, A., Rahman, N., Leung, P. C. K. (2006). Steroid Receptor Coactivator-3 Is Required for Progesterone Receptor Trans-activation of Target Genes in Response to Gonadotropin-releasing Hormone Treatment of Pituitary Cells. J. Biol. Chem. 281: 20817-20824 [Abstract] [Full Text]  
  • Hu, Y. P., Venkateswarlu, S., Sergina, N., Howell, G., Clair, P. St., Humphrey, L. E., Li, W., Hauser, J., Zborowska, E., Willson, J. K. V., Brattain, M. G. (2005). Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells. J. Biol. Chem. 280: 27383-27392 [Abstract] [Full Text]  
  • Proietti, C., Salatino, M., Rosemblit, C., Carnevale, R., Pecci, A., Kornblihtt, A. R., Molinolo, A. A., Frahm, I., Charreau, E. H., Schillaci, R., Elizalde, P. V. (2005). Progestins Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-Dependent Mechanism in Breast Cancer Cells. Mol. Cell. Biol. 25: 4826-4840 [Abstract] [Full Text]  
  • Jacobsen, B. M., Schittone, S. A., Richer, J. K., Horwitz, K. B. (2005). Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology. Mol. Endocrinol. 19: 574-587 [Abstract] [Full Text]  
  • Wu, J., Brandt, S., Hyder, S. M. (2005). Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progestin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells. Mol. Endocrinol. 19: 312-326 [Abstract] [Full Text]  
  • Pierson-Mullany, L. K., Lange, C. A. (2004). Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2. Mol. Cell. Biol. 24: 10542-10557 [Abstract] [Full Text]  
  • Zhang, Y., Hamburger, A. W. (2004). Heregulin Regulates the Ability of the ErbB3-binding Protein Ebp1 to Bind E2F Promoter Elements and Repress E2F-mediated Transcription. J. Biol. Chem. 279: 26126-26133 [Abstract] [Full Text]  
  • Jansen, M. S., Nagel, S. C., Miranda, P. J., Lobenhofer, E. K., Afshari, C. A., McDonnell, D. P. (2004). Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 101: 7199-7204 [Abstract] [Full Text]  
  • Lange, C. A. (2004). Making Sense of Cross-Talk between Steroid Hormone Receptors and Intracellular Signaling Pathways: Who Will Have the Last Word?. Mol. Endocrinol. 18: 269-278 [Abstract] [Full Text]  
  • Qiu, M., Olsen, A., Faivre, E., Horwitz, K. B., Lange, C. A. (2003). Mitogen-Activated Protein Kinase Regulates Nuclear Association of Human Progesterone Receptors. Mol. Endocrinol. 17: 628-642 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»